Cited by 410Cardiomyopathy and Myosin StudiesViral Infections and Immunology ResearchBlood Pressure and Hypertension Studies

The DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.

Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy

Open access

Sherrid, Mark V., Barac, Ivan, McKenna, William J., Elliott, Perry M., Dickie, Shaughan, Chojnowska, Lidia, Casey, Susan, Maron, Barry J.·2005·Journal of the American College of Cardiology

DOI 10.1016/j.jacc.2005.01.012

Open this paper in CoChat — free account

Abstract

Objectives In this study we assessed the long-term efficacy and safety of disopyramide for patients with obstructive hypertrophic cardiomyopathy (HCM).Background It has been reported that disopyramide may reduce left ventricular outflow gradient and improve symptoms in patients with HCM. However, long-term efficacy and safety of disopyramide has not been shown in a large cohort.Methods Clinical and echocardiographic data were evaluated in 118 obstructive HCM patients treated with disopyramide at 4 HCM treatment centers. Mortality in the disopyramide-treated patients was compared with 373 obstructive HCM patients not treated with disopyramide.Results Patients were followed with disopyramide for 3.1 +/- 2.6 years; dose 432 +/- 181 mg/day (97% also received beta-blockers). Seventy-eight patients (66%) were maintained with disopyramide without the necessity for major non-pharmacologic intervention with surgical myectomy, alcohol ablation, or pacing; outflow gradient at rest decreased from 75 +/- 33 to 40 +/- 32 mm Hg (p < 0.0001) and mean New York Heart Association functional class from 2.3 +/- 0.7 to 1.7 +/- 0.6 (p < 0.0001). Forty other patients (34%) could not be satisfactorily managed with disopyramide and required major invasive interventions because of inadequate symptom and gradient control or vagolytic side effects. All-cause annual cardiac death rate between disopyramide and non-disopyramide-treated patients did not differ significantly, 1.4% versus 2.6%/year (p = 0.07). There was also no difference in sudden death rate, 1.0%/year versus 1.8%/year (p = 0.08).Conclusions Two-thirds of obstructed HCM patients treated with disopyramide could be managed medically with amelioration of symptoms and about 50% reduction in subaortic gradient over >/=3 years. Disopyramide therapy does not appear to be proarrhythmic in HCM and should be considered before proceeding to surgical myectomy or alternate strategies.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.jacc.2005.01.012

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Hypertrophic Cardiomyopathy: A Systematic Review
Maron, B. J. (2002) · JAMA · doi:10.1001/jama.287.10.1308 · Cited by 2,224
Self-citation
Hypertrophic Cardiomyopathy
Hypertensive, Y., & Chin, K. (1982) · Springer eBooks · doi:10.1007/978-3-642-68282-7 · Cited by 1,757
American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy
Maron, B. J., McKenna, W. J., Danielson, G. K., KAPPENBERGER, L. J., Kuhn, H. J., Seidman, C. E., Shah, P. M., Spencer, W. H., Spirito, P., ten Cate, F. J., et al. (2003) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(03)00941-0 · Cited by 1,572
Effect of Left Ventricular Outflow Tract Obstruction on Clinical Outcome in Hypertrophic Cardiomyopathy
Maron, M. S., Olivotto, I., Betocchi, S., Casey, S. A., Lesser, J. R., Losi, M. A., Cecchi, F., & Maron, B. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021332 · Cited by 1,259
Magnitude of Left Ventricular Hypertrophy and Risk of Sudden Death in Hypertrophic Cardiomyopathy
Spirito, P., Bellone, P., Harris, K. M., Bernabò, P., Bruzzi, P., & Maron, B. J. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006153422403 · Cited by 1,142
Hypertrophic cardiomyopathy. The importance of the site and the extent of hypertrophy. A review
Wigle, E. D., Sasson, Z., Henderson, M. A., Ruddy, T. D., Fulop, J. C., Rakowski, H., & Williams, W. G. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/0033-0620(85)90024-6 · Cited by 822
Hypertrophic Cardiomyopathy
Wigle, E. D., Rakowski, H., Kimball, B. P., & Williams, W. G. (1995) · Circulation · doi:10.1161/01.cir.92.7.1680 · Cited by 775
Idiopathic Hypertrophic Subaortic Stenosis: I. A Description of the Disease Based Upon an Analysis of 64 Patients
D, E. B. M., Lambrew, C. T., Rockoff, S. D., Ross, J., & Morrow, A. G. (1964) · Circulation · doi:10.1161/01.cir.29.5s4.iv-3 · Cited by 758
Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy
Elliot, P. M., Gimeno, J. R., Mahon, N., Poloniecki, J. D., & McKenna, W. J. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04005-8 · Cited by 517
Hypertrophic Cardiomyopathy
Behr, E. R., & McKenna, W. J. (2002) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-002-0039-8 · Cited by 407

Flagged first, then by citations

Show all 52 references

2 of the 52 references couldn’t be matched to a known paper.

Sorted by citations

Items 301–400 of 409

New Frontiers in Hypertrophic Obstructive Cardiomyopathy
Parniani, A., Carroll, D., & Cios, T. J. (2024) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2024.09.005 · Cited by 2
The clinical utility of cardiac myosin inhibitors for the management of hypertrophic cardiomyopathy: a scoping review
Othman, L., Koskina, L. E., Huerta, N. H., & Rao, S. J. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10476-w · Cited by 1
Cardiac Hypertrophy: A Comprehensive Review from Prenatal Life to Young Adulthood
Avesani, M., Pomiato, E., Moscatelli, S., Sabatino, J., Borrelli, N., Luedke, L., Sarro, R. D., Pavesi, S., Pelaia, G., Mastellone, C., et al. (2025) · Children · doi:10.3390/children12080989 · Cited by 1
“Its dose escalation is typically limited by its anticholinergic side effects [84,85].”
Rifampicin for the treatment of a cardiogenic shock related to mavacamten toxicity: the worse and the best of drug interactions from a case report
Lucas, S., Hennart, B., de Groote, P., Lamblin, N., Ridon, H., Dupré, C., Lionet, A., & Lemesle, G. (2026) · European Heart Journal - Case Reports · doi:10.1093/ehjcr/ytag368 · Cited by 1
Comparison between Carotid Artery Doppler Ultrasound and Coronary Calcium Score as Predictors of Significant Coronary Artery Disease in Patients Undergoing Computed Tomography Coronary Angiography
Tresoldi, S. (2014) · Cardiovascular Pharmacology Open Access · doi:10.4172/2329-6607.1000116 · Cited by 1
Tratamiento farmacológico de la fibrilación auricular. Antiarrítmicos y anticoagulantes orales
Cosı́n-Sales, J., & Olalla, J. J. (2016) · Revista Española de Cardiología Suplementos · doi:10.1016/s1131-3587(16)30012-7 · Cited by 3
The evaluation and management of decompensated hypertrophic cardiomyopathy in the emergency department
Gardner, M., Nair, V., Hu, D. J., & Derry, S. (2018) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2018.09.003 · Cited by 1
Managing the High-Risk Patient: Critical Care, TAVR, MitraClip, Pressors, and Cardiac Assist Devices
Wong, T. C., DePasquale, E. C., & Baas, A. S. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_25 · Cited by 1
Pharmacotherapy for hypertrophic cardiomyopathy
Игнатенко, Г. А., Тарадин, Г. Г., & Kononenko, L. V. (2023) · South Russian Journal of Therapeutic Practice · doi:10.21886/2712-8156-2023-4-4-6-13 · Cited by 1
Long-term follow-up study on obstructive hypertrophic cardiomyopathy patients treated with disopyramide: evidences of a notable trend in symptom control within a real-world clinical setting
Todde, G., Dei, L., Polizzi, R., Gabrielli, D., Canciello, G., Romano, S., Borrelli, F., Hálasz, G., Ordine, L., Napoli, S., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1416600 · Cited by 1
Treatment options for hypertrophic obstructive cardiomyopathy: a patient-centric review
Cirillo, C., Perillo, A., Monda, E., Palmiero, G., Verrillo, F., Rubino, M., Diana, G., Dongiglio, F., Caiazza, M., Cirillo, A., et al. (2024) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2024.2436659 · Cited by 1
“Further studies confirmed its efficacy in reducing LVOTO and improving symptoms related to obstruction [47].”
Identification of SERPINE1 as a therapeutic target in hypertrophic cardiomyopathy via bioinformatics analysis and experimental validation
Al‐Maamari, A., Sultan, M., Ding, S., Wu, S., Zhang, T., Qiao, R., Duan, Y., Chen, N., Wu, D., Liu, G., et al. (2025) · Gene Reports · doi:10.1016/j.genrep.2025.102150 · Cited by 1
Atrial fibrillation and thromboembolic risk in hypertrophic cardiomyopathy
Choi, Y.-J., & Lakdawala, N. K. (2025) · Journal of Cardiovascular Imaging · doi:10.1186/s44348-025-00057-2 · Cited by 2
“However, use remains limited by anticholinergic side effects, the need for inpatient initiation in some cases, and limited availability [106].”
Hypertrophic cardiomyopathy
Colan, S. D. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-13279-7.00036-5 · Cited by 1
Evaluation and Management of Hypertrophic Cardiomyopathic Patients Through Noncardiac Surgery and Pregnancy
Hensley, N. B., & Abraham, T. P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_22 · Cited by 1
Hypertrophic Cardiomyopathy (HCM)
Song, P. (2017) · Springer eBooks · doi:10.1007/978-3-319-50141-3_9 · Cited by 1
Valvular Heart Disease in Critical Care
Turi, Z. G. (2008) · Elsevier eBooks · doi:10.1016/b978-032304841-5.50035-2 · Cited by 1
Prophylactic Antiarrhythmic Drug Therapy in Atrial Fibrillation.
Rodríguez‐Mañero, M., Sarkozy, A., Chierchia, G. B., Casado-Arroyo, R., Ricciardi, D., de Asmundis, C., Carlo de, A., & Sarkozy, P. (2013) · Europe PMC (PubMed Central) · doi:10.4022/jafib.636 · Cited by 1
Positive inotropic drugs and drugs used in dysrhythmias
Aronson, J. K. (2008) · Side effects of drugs annual · doi:10.1016/s0378-6080(08)00017-2 · Cited by 1
Disopyramide for symptomatic obstructive hypertrophic cardiomyopathy
Sherrid, M. V., & Massera, D. (2025) · International Journal of Cardiology · doi:10.1016/j.ijcard.2025.133030 · Cited by 1
Hypertrophic Cardiomyopathy: Pathophysiology, Genetics and Invasive Treatment
Michels, M. (2011)
Pacientes com cardiomiopatia hipertrófica obstrutiva tratados com redução septal percutânea. Análise da evolução tardia
de Cano, S. J. F. (2014) · doi:10.11606/t.98.2014.tde-16032015-091641
Arrhythmias and Hypertrophic Cardiomyopathy
Nair, K., CAMERON, D. A., Moravsky, G., & BUTANY, J. W. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5316-0_19
Pediatric Diagnosis and Management
Colan, S. D. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_9
Hypertrophic Cardiomyopathy - The Case for Alcohol Ablation Therapy
Tsilakis, D., Haveles, I., & Manolis, A. S. (2008) · Hospital chronicles/Hospital Chronicles · doi:10.2015/hc.v4i2.326
“Disopyramide has also been proven effective, especially in combination with beta-blockers owing to its negative inotropic effects and no evidence of proarrhythmia in these patients.(13) When atrial fibrillation complicates the clinical course of HCM it requires aggressive intervention with anticoagulation, attempts to…”
Background
Perspectives on Catheter Ablation of Atrial Fibrillation
Takahashi, Y. (2014) · Circulation Journal · doi:10.1253/circj.cj-14-1363
17 Positive inotropic drugs and drugs used in dysrhythmias
Aronson, J. K. (2007) · Side effects of drugs annual · doi:10.1016/s0378-6080(06)29017-2
Tratamiento de la obstrucción al tracto de salida del ventrículo izquierdo en la miocardiopatía hipertrófica
Sorzano, E. S., Pereira, E. P., García‐Pavía, P., & Alonso-Pulpón, L. A. (2009) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/s0304-5412(09)72616-2
Anestesia para Salpingectomia Parcial Bilateral em Paciente com Miocardiopatia Hipertrófica Idiopática. Relato de um Caso e Revisão da Literatura* Anesthesia for Partial Bilateral Salpingectomy in a Patient with Idiopathic Hypertrophic Cardiomyopathy. Case Report and Review of the Literature*
Clínica, I., Sofia, A., Sardi, D. C., Ramboa, G., & Sardi, N. S. (2010)
Preventing Recurrences: Classic and Modern Antiarrhythmic Drugs in Atrial
Víctor, F., Jorge, T. R., & Lozano, I. F. (2015)
Srce i krvni Sudovi
Beleslin, B., Deljanin, M., Kanjuh, V., Parapid, B. J., Giga, V. L., Prostran, M. S., Angelkov, L., Balinovac, J., Bikicki, M., Ambrosio, G., et al. (2013)
Treatment of Atrial Fibrillation and Atrial Flutter
Christ, T., Pecha, S., & Jost, N. (2015) · Springer eBooks · doi:10.1007/978-3-319-15961-4_50
Lázaro Isralys Aldama Pérez I , Ángel Abreu Cruz II , Aylén Pérez Barreda III , Ana Liuvys Cuba Rodríguez IV , Luis Miguel Morales Pérez V , Eliezer San Román
Vi, G. (2014)
Tools and Techniques: Alcohol septal ablation for hypertrophic obstructive cardiomyopathy
Bertog, S. C., Franke, J., Hornung, M., Hofmann, I., Sievert, H., Kahlert, P., Pręgowski, J., Ramcharitar, S., Naber, C. K., & Krankenhaus, E. (2013)
Treatments for Hypertrophic Obstructive Cardiomyopathy
Herrmann, H. C. (2005) · Journal watch · doi:10.1056/jc200506170000002
Better research is needed to develop, subclassify, and identify new therapeutic targets, which hold the promise that precise therapies aimed at preventing or reversing AF will be developed. Antiarrhythmic therapeutic strategies for AF should be focused on controlling pathophysiologic re- modeling, with better prevention and disease-modifying strategies.
Sardar, M. R., Saeed, W., & Kowey, P. R. (2014)
Key HCM References
Maron, B. J., & Salberg, L. R. (2006) · doi:10.1002/9780470750896.refs
Outpatient Medications in Atrial Fibrillation
Newby, L. K., & Pokorney, S. D. (2016) · Contemporary cardiology · doi:10.1007/978-3-319-31386-3_18
Hypertrophic Cardiomyopathy and Related Conditions
Ragosta, M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-48042-0.00006-3
Cardiomyopathies in the Elderly
McClung, J. A., Nanna, M., & Aronow, W. S. (2008) · Fundamental and clinical cardiology · doi:10.3109/9781420061710.019
and future hypertrophic cardiomyopathy: past, present Left ventricular outflow tract obstruction in
Ommen, S. R., Shah, P. M., & Tajik, A. J. (2010)
Heart Failure as a Consequence of Restrictive Cardiomyopathy
Marian, A. J. (2010) · Elsevier eBooks · doi:10.1016/b978-1-4160-5895-3.10025-7
Stroke and atrial fibrillation in hypertrophic cardiomyopathy
Guttmann, O. P. (2015) · UCL Discovery (University College London)
Anesthesia for Partial Bilateral Salpingectomy in a Patient with Idiopathic Hypertrophic Cardiomyopathy. Case Report and Review of the Literature
Sardi, A. S. D. C., Ramboa, G., & Sardi, N. S. (2010) · Brazilian Journal of Anesthesiology · doi:10.1016/s0034-7094(10)70007-6
Arrhythmias in Cardiomyopathy
Roukoz, H., Adkisson, W. O., Akdemir, B., Krishnan, B., Sakaguchi, S., & Benditt, D. G. (2017) · Springer eBooks · doi:10.1007/978-3-319-44577-9_19
Hypertrophic Cardiomyopathy and Related Conditions
Ragosta, M. (2008) · Elsevier eBooks · doi:10.1016/b978-141604000-2.10006-4
Inherited Cardiac Muscle Disorders: Hypertrophic and Restrictive Cardiomyopathies
Akhtar, M. M., Kaski, J. P., & Elliot, P. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-66114-8_9
Hypertrophic, Restrictive, and Infiltrative Cardiomyopathies
Lakdawala, N. K., & Dec, G. W. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4557-0101-8.00017-5
Surgical septal myectomy for obstructive hypertrophic cardiomyopathy during infancy
Schleihauf, J., Cleuziou, J., & Wolf, C. M. (2019) · Translational Pediatrics · doi:10.21037/tp.2018.12.01
Atrial Fibrillation
Kumar, S., & Michaud, G. F. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-44733-1.00076-6
Out With the Old and in With the New
Maron, M. S. (2019) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2019.10.002
“(8), as well as prior prospective clinical studies with disopyramide (3,4,9), suggest that the minimal negative inotropic effect of disopyramide is not associated with increased risk.”
BackgroundResult
Hypertrophic Cardiomyopathy
Yao, D., & Ramasubbu, K. (2009) · Elsevier eBooks · doi:10.1016/b978-032304525-4.00029-0
Miocardiopatía hipertrófica
Hagège, A. A. (2013) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(13)65334-9
Hypertrophic Cardiomyopathy
Cunningham, L. C., & Ramasubbu, K. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4815-0.00027-1
Hypertrophic obstructive cardiomyopathy with left ventricular outflow and mid obstruction with apical aneurysm: a case report
Misumi, I., Sato, K., Nagano, M., Yamada, Y., Urata, J., Kaikita, K., & Tsujita, K. (2020) · Journal of Echocardiography · doi:10.1007/s12574-020-00486-6
Hypertrophic Cardiomyopathy: Genetics, Pathogenesis, Diagnosis, Clinical Course and Therapy
Lazzeroni, D., & Centorbi, C. S. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.97033
“If ß-blockers alone are ineffective, disopyramide can be added, titrated up to a maximum tolerated dose [127, 128] because can abolish basal LV outflow pressure gradients and improve exercise tolerance and functional capacity without pro-arrhythmic effects [129–131].”
Background
Systolic Heart Failure in a Patient With Hypertrophic Obstructive Cardiomyopathy
Whitten, S. E. (2008) · Critical Care Nurse · doi:10.4037/ccn2008.28.5.44
“Disopyramide, on the other hand, is used to reduce resting gradients and is best used in combination with a β-blocker.(10,18)”
Background
Short-term outcomes of surgical atrial ablation and septal myectomy
Сергеевич, З. А., Bogachev-Prokophiev, A. V., Afanasyev, A. V., Махарамович, Ш. Р., Sapegin, A. V., Budagaev, S. A., Иванович, Ж. С., & Иванович, Д. И. (2021) · Patologiya krovoobrashcheniya i kardiokhirurgiya · doi:10.21688/1681-3472-2021-3-51-60 · Cited by 2
The clinical characteristics of families with hypertrophic cardiomyopathy associated with mutations of cardiac myosin binding protein C
Page, S. P. (2010) · UCL Discovery (University College London)
1. Up-to-date on Drug Therapy for Chronic Heart Failure
Obata, H., & Minamino, T. (2014) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.103.378
Hypertrophic Cardiomyopathy
Hanna, E. B. (2022) · doi:10.1002/9781119832737.ch7
Medical Therapy: From Beta-Blockers to Disopyramide
Mankowitz, K., & Sherrid, M. V. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_15
Pediatric Diagnosis and Management
Colan, S. D., & Miliaresis, C. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_9
Abordagem Terapêutica na Cardiomiopatia Hipertrófica, uma Revisão Integrativa
Barreto, E. A., Cassaniga, R. A., & de Aragão, I. P. B. (2022) · Revista de Saúde · doi:10.21727/rs.v13i1.2794
Miocardiopatía hipertrófica
Hagège, A. A. (2019) · EMC - Tratado de Medicina · doi:10.1016/s1636-5410(19)42599-3
Antiarrhythmic Drugs
López-Magallón, A., Welchering, N., Pacheco, J. T., Berry, D., & Munoz, R. A. (2013) · Springer eBooks · doi:10.1007/978-1-4471-4619-3_64
Disopyramide
(2015) · Elsevier eBooks · doi:10.1016/b978-0-444-53717-1.00648-x
Miocardiopatías
García, M. V., Huertas, L. J., & Gimeno, J. R. (2013) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/s1134-2072(13)70555-3
Cardiomyopathie hypertrophique
Hagège, A. A. (2013) · EMC - Traité de médecine AKOS · doi:10.1016/s1634-6939(13)59288-x
ANTIDYSRHYTHMIC DRUGS
(2009) · Elsevier eBooks · doi:10.1016/b978-0-444-53268-8.50006-5
Discussion
(2010) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2009.07.080
Further reading
Maron, B. J., & Salberg, L. R. (2014) · doi:10.1002/9781118725498.furread
Evaluation and Management of Hypertrophic Cardiomyopathic Patients Through Noncardiac Surgery and Pregnancy
Hensley, N. B., & Abraham, T. P. (2018) · Springer eBooks · doi:10.1007/978-3-319-92423-6_29
Post Dialysis Hypotension, New Diagnosis of HOCM
Rohani, A. (2023) · Clinical cases in cardiology · doi:10.1007/978-3-031-24528-2_11
Management of Hypertrophic Cardiomyopathy
Maron, B. J. (2009) · doi:10.1002/9781444309768.ch49
Hypertrophic Cardiomyopathy in Children
Margossian, R. E., & Colan, S. D. (2023) · Springer eBooks · doi:10.1007/978-3-030-42937-9_76-1
Avaliação de variáveis ecocardiográficas associadas ao resultado da ablação septal por radiofrequência na miocardiopatia hipertrófica obstrutiva
Shinzato, M. H. (2022) · doi:10.11606/d.98.2022.tde-26062023-151733
Fever Unveiling a Hidden Cardiac Condition: A Case of Pediatric Hypertrophic Obstructive Cardiomyopathy
Reddy, S., Varma, A., & Taksande, A. M. (2024) · Cureus · doi:10.7759/cureus.55823
“Beta-blockers, such as Propranolol, are commonly prescribed to mitigate LVOT obstruction and improve clinical outcomes [4].”
Background
MIECTOMIA SEPTAL E ABLAÇÃO SEPTAL ALCOÓLICA PARA CONTROLE CLÍNICO DE PACIENTES COM CARDIOMIOPATIA HIPERTRÓFICA OBSTRUTIVA: UMA REVISÃO INTEGRATIVA
Girardi, J. M., Vieira, L. S. L., Andrade, G. M. A., Andrade, I. R., Silva, V. D. C., & do Couto, A. A. (2024) · Revista Foco · doi:10.54751/revistafoco.v17n3-133
Use of Disopyramide in Obstructive Hypertrophic Cardiomyopathy: A European Insight
Charron, P., Osman, F., Trochu, J., Zema, C., Hurst, M. A., Sandler, B. C., Cotté, F.-E., Lemmer, T., & Tome, M. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15114234
Spezielle medikamentöse und interventionelle Therapieverfahren der hypertrophen Kardiomyopathie
Seggewiß, H., & Batzner, A. (2024) · Aktuelle Kardiologie · doi:10.1055/a-2285-3854
Hypertrophic Cardiomyopathy in Children
Margossian, R. E., & Colan, S. D. (2024) · Springer eBooks · doi:10.1007/978-3-031-07563-6_76
How effective is disopyramide in treating pediatric hypertrophic cardiomyopathy? State of the art and future directions
Vecchio, K. D., Rizzardi, C., Pozza, A., Prati, F., Ye, L., Fattoretto, A., Reffo, E., & Salvo, G. D. (2024) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2024.3084
Guías mexicanas 2024 para el diagnóstico y tratamiento de la miocardiopatía hipertrófica
Llamas‐Esperón, G. A., Berrios-Bárcenas, E. A., Cossío-Aranda, J. E., Guerra-López, A., Magaña‐Serrano, J. A., Iturralde-Torres, P., Lara-Vargas, J. A., Meave‐González, A., Rosas, E. A., Ilazarra-Lomelí, H., et al. (2025) · Archivos de cardiología de México · doi:10.24875/acm.m25000098
Class I Antiarrhythmic Drugs: Na+ Channel Blockers
Shenasa, M., & Soleimanieh, M. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_3
AAD in Patients with Comorbidities
Sartiani, L., & Cerbai, E. (2024) · Springer eBooks · doi:10.1007/978-3-031-74046-6_14
Hypertrophic Cardiomyopathy and Related Disorders
Ragosta, M., & Ayers, M. P. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-11642-1.00007-1
Dose–response relationship in the modeling acute toxic hepatitis in vivo as a basis for identifying new correction strategies
Ryabova, Y. V., Karimov, D. O., Repina, E. F., Якупова, Т. Г., Khusnutdinova, N. Y., & Smolyankin, D. A. (2025) · Сибирский научный медицинский журнал · doi:10.18699/ssmj20250212
Mavacamten en miocardiopatía hipertrófica obstructiva sintomática
Vaca, E. R. (2025) · Panorama actual del medicamento · doi:10.63105/49.482.5
Hypertrophic Cardiomyopathy in Iran: General Characteristics, Clinical Presentations, Imaging Features, and Major Adverse Cardiovascular Events of 322 Patients
Rostambeigi, S., Hamidabad, N. M., Nadri, S., Alizadehasl, A., Hashemi, E., Pouraliakbar, H., & Sadeghpour, A. (2025) · Heart Views · doi:10.4103/heartviews.heartviews_155_24
“[31] In our study, 20.4% of patients with obstructive form received disopyramide, However, myosin inhibitor was not an option at the time of this study.”
Influential
Disopyramide Therapy in Cats with Obstructive Hypertrophic Cardiomyopathy Non-Responsive to Carvedilol
Satomi, S., Suzuki, R. H., Yuchi, Y., Kanno, H., Nomura, M., Teshima, T., & Matsumoto, H. (2025) · Veterinary Sciences · doi:10.3390/vetsci12100999
“Furthermore, a previous report noted only a slight QT prolongation, which did not necessitate discontinuation of disopyramide [14].”
Influential
Myosin inhibitors for the treatment of obstructive hypertrophic cardiomyopathy: a Canadian perspective on a first-in-class therapy
Lau, W., Dababneh, S., Ong, K. C., Yeung, D. F., Sanatani, S., & Roston, T. M. (2025) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2025-0124
Managing the Critical Patient with HCM
Wong, T. C., & Baas, A. S. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_26
Evaluation and Management of Hypertrophic Cardiomyopathic Patients Through Noncardiac Surgery and Pregnancy
Abozaid, R., Hensley, N. B., Abraham, T. P., & Wong, T. C. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_30
Pediatric Diagnosis and Management
Miliaresis, C., Warsy, I. A., & Colan, S. D. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_13
Pharmacologic Therapy of Hypertrophic Cardiomyopathy 1964–2024: From Beta-Blockers to Disopyramide
Sherrid, M. V., & Massera, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_18
Management of Arrhythmia: Medications, Diagnostic Studies, and Catheter Ablation
Iwai, S., Germano, J. J., & Jacobson, J. T. (2025) · Springer eBooks · doi:10.1007/978-3-031-99282-7_22
Hypertrophic obstructive cardiomyopathy—a cardiologist’s perspective
Bahl, A. (2025) · Indian Journal of Thoracic and Cardiovascular Surgery · doi:10.1007/s12055-025-02105-4
“This benefit persisted for the duration of follow-up, which was over 3 years [19].”
Inherited Myocardial Diseases
Calcagnino, M. M., & McKenna, W. J. (2010) · Springer eBooks · doi:10.1007/978-1-84996-153-0_2
Medical Therapy: From Beta–Blockers to Disopyramide
Mankowitz, K. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4956-9_14

Authors: Sherrid, M. V., Barac, I., McKenna, W. J., Elliott, P. M., Dickie, S., Chojnowska, L., Casey, S., & Maron, B. J.
Affiliations: St. Luke's-Roosevelt Hospital Center (US)
St George's, University of London (GB)
Institute of Cardiology (PL)
Minneapolis Heart Institute Foundation (US)
Corresponding author: Sherrid, Mark V.
ORCID: Sherrid, Mark V.
McKenna, William J.
Casey, Susan
Maron, Barry J.
Venue: Journal of the American College of Cardiology
Publisher: Elsevier BV
Published: 2005-04
Volume: 45
Issue: 8
Pages: 1251-1258
ISSN: 0735-1097 (ISSN-L)
DOI: 10.1016/j.jacc.2005.01.012
OpenAlex: W1992100033
Cited by: 410
References: 52
Citations by year: 2026: 12 · 2025: 35 · 2024: 34 · 2023: 24 · 2022: 23 · 2021: 23 · 2020: 20 · 2019: 14 · 2018: 19 · 2017: 16 · 2016: 15 · 2015: 17 · 2014: 27 · 2013: 18 · 2012: 22
FWCI: 8.45
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3065 d)
Locations: Journal of the American College of Cardiology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiomyopathy and Myosin Studies
Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
Keywords: disopyramide, hypertrophic obstructive cardiomyopathy, left ventricular outflow tract gradient, long-term efficacy, drug safety, sudden cardiac death, cardiac mortality, drug-induced arrhythmia, beta-blockers, myectomy, alcohol septal ablation, NYHA functional class
MeSH terms: Administration, Oral, Adrenergic beta-Antagonists, Anti-Arrhythmia Agents, Cardiomyopathy, Hypertrophic, Disopyramide, Echocardiography, Female, Humans, Male, Middle Aged, Myocardial Contraction, Safety, Death, Sudden, Cardiac, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks